On June 23, 2022 Immunicum, a biopharmaceutical company focused on improving survival outcomes for cancer patients with tumor recurrence through cell-based immunotherapies, reported that it has changed its corporate name from Immunicum AB to Mendus AB (Press release, Immunicum, JUN 23, 2022, View Source [SID1234623752]). The name change is effective as of today and is approved by the Swedish Companies Registration Office. The rebranding to "Mendus" reflects the Company’s maturing clinical pipeline and its broader positioning in cancer recurrence immunotherapy. In addition, this marks an important operational transition as the Company continues to mature with a longer-term focus on a global reach. The Company will continue trading under the ticker symbol "IMMU.ST" and the new website for Mendus AB is www.mendus.com.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Today’s news marks an exciting step in a transformative period for the Company. Initiated with the merger and integration of Immunicum and DCprime and accelerated by subsequent directional pipeline decisions and promising novel R&D initiatives, these developments have resulted in a multi-faceted and broader long-term vision for the Company. The name Mendus captures our continued commitment to develop therapies that delay or reduce cases of cancer recurrence, while preserving the quality of life of people living with cancer," commented Erik Manting, PhD, Chief Executive Officer of Mendus. "As we move forward in this new phase of important growth, we look forward to continuing our dedicated work in the development of safe and effective cell-based therapies that we believe can significantly decrease the chance of cancer relapse and improve overall survival."

The Company received approval from its shareholders for the name change at the Annual General Meeting on May 10, 2022 and has since implemented the required legal and organizational changes. Mendus will continue to operate from its headquarters in Stockholm, Sweden, with an office in Gothenburg, Sweden and its main R&D center in Leiden, The Netherlands, which will be operating as a fully owned subsidiary Mendus BV. The Company’s stock ticker symbol will stay unchanged and Mendus AB will continue trading under the ticker symbol IMMU.ST at the Nasdaq Stockholm Main Market section.

In May 2022, the Company presented positive interim results from its ongoing ADVANCE II clinical study evaluating its most advanced proprietary development program, the cancer relapse vaccine DCP-001, as a maintenance therapy option in acute myeloid leukemia (AML). The trial is continuing follow-up of patients and Mendus expects to report on the status of key survival endpoints and immunomonitoring data in the fourth quarter of 2022. Mendus is preparing to advance the development of DCP-001 into a subsequent clinical study in AML maintenance and working to establish a scalable manufacturing infrastructure for the continued development of the program. The company also explores cancer relapse vaccination in ovarian cancer in an ongoing Phase I trial and is preparing for a signal-confirmatory trial in gastro-intestinal stromal tumors with its intratumoral immune primer ilixadencel. Mendus has established a broad collaboration network to further leverage its expertise in allogeneic dendritic cell biology to design novel immunotherapeutic approaches.

On June 23, 2022 GTC reported that it is honored to participate in a webinar hosted by RUNX1 and the MDS Foundation: Get Free Access to Genetic Testing for Underserved MDS and Hematologic Malignancy Patients (Press release, Genomic Testing Cooperative, JUN 23, 2022, View Source [SID1234618944])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will take place on June 23rd at 12:00 PM PST or 3 PM EST.

Register link: https://bit.ly/WebinarJune23

Agenda:

Intro:

Tracey Iraca, Executive Director – MDS Foundation

Katrin Erickson, Executive Director – RUNX1

Making Diagnosis of Hematologic Neoplasms in the Era of Genomics Available to All by Dr. Maher Albitar, CEO/CMO of Genomic Testing Cooperative

Value of Molecular Profiling for MDS by Dr. Rafael Bejar, UCSD Moores Cancer Center

Q&A

Please register by Tuesday, June 22nd. Upon registering, you will receive an email with a webinar link and a PASSWORD to connect through Zoom.

On June 23, 2022 Triumvira Immunologics reported At least 17 cell therapy programs are targeting solid tumor-selective HER2, 10 of which are CAR T cells. Companies are also expressing HER2 CARs on other cell types such as NK cells, myeloid cells, and macrophages (Press release, Triumvira Immunologics, JUN 23, 2022, View Source [SID1234616492]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CAR T cell therapies have been highly effective against hematological malignancies, but solid tumors have been more challenging. Overcoming the major obstacles, including a lack of highly tumor-selective solid tumor targets, was a major theme at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting in April.

On June 23, 2022, DiaMedica USA Inc. (the "Tenant"), a Delaware corporation and wholly owned subsidiary of DiaMedica Therapeutics Inc., a corporation existing under the laws of British Columbia, Canada (the "Company"), entered into an office lease (the "Lease") with Medica Services Company, LLC, a Delaware limited liability company (the "Landlord"), whereby the Tenant agreed to lease approximately 6,175 square feet at 301 Carlson Parkway, Suite 210, Minnetonka, Minnesota, USA 55305 (the "Premises") (Filing, 8-K, DiaMedica, JUN 23, 2022, View Source [SID1234616393]). The Lease has an initial term of five years and five months, commencing on September 1, 2022, and the Tenant has the option to extend the Lease for an additional five years. The Company intends to relocate its principal executive offices, together with its research and development operations, to the Premises on September 1, 2022 following the expiration of the Tenant’s current lease in August 2022.

Under the Lease, the Tenant has agreed to pay rent, after an initial five-month abatement period, in an initial amount equal to approximately $9,000 per month, plus its pro rata share of operating expenses and real estate taxes. The Lease contains customary representations, warranties, covenants, indemnification provisions, default provisions, and other provisions.

As an inducement to the Landlord to enter into the Lease with the Tenant, on June 22, 2022, the Company entered into a lease guaranty agreement (the "Lease Guarantee Agreement") pursuant to which the Company agreed to fulfill and perform or cause the Tenant to fulfill and perform all of the terms and every payment, covenant and condition which the Tenant is required to make or perform under the Lease. The Lease Guarantee Agreement terminates once full payment of all sums due under the Lease and full performance of all terms, covenants and conditions therein have been kept, observed or performed by the Tenant.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On June 23, 2022 Kuraray Co., Ltd. (Head Office: Chiyoda-ku, Tokyo; President: Hitoshi Kawahara; hereinafter "Kuraray") reported that it has published the Kuraray Report 2022, an integrated report (A4 size, 58 pages, full color) (Press release, Kuraray, JUN 23, 2022, View Source [SID1234616231]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The aim of the Kuraray Report is to help shareholders, investors, and all other stakeholders better understand the value that the Kuraray Group creates over the medium to long term by providing a comprehensive overview of financial and non-financial information, including environmental, social and governance data.
Going forward, the Kuraray Group will continue to hold constructive dialogues with its stakeholders while also enhancing the content of the report.

Front cover of the Kuraray Report 2022
Cover of the Kuraray Report 2022
Overview of the Kuraray Report 2022
This year’s report focuses on the initiatives under the medium-term management plan "PASSION 2026," which started in fiscal 2022. The "PASSION 2026" is a medium-term management plan to realize the long-term vision "Kuraray Vision 2026," which was revised for Kuraray’s 100th anniversary, and our newly articulated sustainability long-term vision. In "PASSION 2026", the Kuraray Group has identified "Our Challenges," three areas that must be addressed in order to achieve sustainable growth, and these are introduced along with messages from top management. Under "Our Challenges," Sustainability as an Opportunity (Sustainability medium-term plan), we adopt the 3P model, which is defined by the three Ps of Planet, Product, and People. In this report, we explain each measure being taken in concrete terms to clearly convey the Kuraray Group’s approach and efforts toward sustained development.
To read this report, please click on the following link:

View Source
Sustainability Section of Kuraray’s Corporate Website
The sustainability section of Kuraray’s corporate website features detailed sustainability-related information about initiatives, activities and their results for fiscal 2021 not fully covered in the report. The site uses responsive web design, making it easy to view on smartphones and tablets.
In addition, the sustainability section reports are created in line with the GRI Standards, international guidelines for sustainability reports.